Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 134

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 134
---
477
    )

    (42
    )%

    Chemistry Manufacturing
    and Controls (“CMC”)

    388,629

    (133,780
    ) 

    522,409

    390
    %

    IP Services

    2,525

    10,654

    (8,129
    )

    76
    %

    Total
     
    $
    514,814

    $
    12,955

    $
    501,859

    3,874
    %

The
Company incurred increased research and development expenses for the three months ended June 30, 2025, as compared to the corresponding
period in 2024 primarily as a result of an increase in CMC fees.

Professional
Fees

We
incurred professional expenses for the three months ended June 30, 2025 and 2024 of $1,605,525 and $541,257, respectively. For
the three months ended June 30, 2025, compared to the same period in 2024, this represented an increase of $1,064,268, or 197%,
as a result of increased legal and accounting fees in 2025 due to the Company’s merger.

Other
Expense

We
incurred other expense for the three months ended June 30, 2025 of $218,516 as compared to other expense for the three months
ended June 30, 2024 of $7,533. For the three months ended June 30, 2025, compared to the same period in 2024, this represented
a decrease of $210,983 or 2,801%. The other expense for the three months ended June 30, 2025 and 2024 was primarily the result
of an increased interest expense. The increase in the interest expense was due to the increased number and dollar amount of notes
held by the Company.

 Comparison
of the Six Months Ended June 30, 2025 and 2024

The
following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

    Six
    Months Ended June 30, 2025 and 2024

    2025

    2024

    $
    Change

    %
    Change

    OPERATING EXPENSES

    General and administrative expenses
     
    $